| Acceptance rate | 46% |
|---|---|
| Time to first decision | 6 months* |
| Time to decision with review | 50 days* |
*Approximate number of days
**The days mentioned above are averages and do not indicate exact durations. The process may vary for each article.
ACTA Pharmaceutica Sciencia
2024 , Vol 62 , Num 4
Rasagiline mesylate mucoadhesive buccal microsphere-loaded gel formulations: A new candidate for non-oral Parkinson"s treatment
1 Ege University, School of Pharmacy, Department of Pharmaceutical Technology, Izmir, Türkiye2 Katip Celebi University, School of Pharmacy, Department of Biochemistry, Izmir, Türkiye
DOI : 10.23893/1307-2080.APS6258 Viewed : 483 - Downloaded : 110 Parkinson"s disease (PD) is one of the most common neurological diseases worldwide and affects over 10 million people around the world. Mucosal administration as an alternative to oral administration is very important for the patient"s compliance with the treatment. The purpose of this study Rasagiline mesylate (RM) microspheres (MS) and RM MS-loaded gel formulations were developed and evaluated. Particle size, encapsulation efficiency, and loading capacity of MS were evaluated. For buccal administration, mucoadhesive RM MS was dispersed in chitosan (Chi) gels and characterized from the point of viscosity, mechanical, mucoadhesive, rheological, and release properties. The in-vitro cytotoxic effects of RM microspheres and RM MS-loaded gel formulation were tested against human embryonic kidney epithelial cells (HEK-293T) and mouse embryonic fibroblast cells (NIH/3T3) lines. The tested formulations did not have toxic effects on cells after 12 hours. RM MS-loaded gel formulation was successfully prepared and evaluated. Keywords : Parkinson"s disease, Rasagiline mesylate, mucoadhesive, buccal delivery, microspheres